Epizyme: Why Is Big Pharma Interested In This Small Biotech?

• Epizyme has million-dollar collaborations with a number of big pharma companies.
• The company does not yet have any Phase 2 results.
• However, the company is a pioneer in HMT inhibitors.
• Related inhibitors, HDACs and DNMTs, have been very successful.
• The company has enough cash to see it through trials.

By Dr. Udaya K Maiya, MBBS, MD, DNB, DCCF-Paris

Epizyme's (NASDAQ:EPZM) unique selling proposition is that despite being an early-stage company, it is a leader in a subclass of a class of drugs that has seen considerable success. That broad class has had a number of big pharma involvement; however, Epizyme's particular niche is dominated by one company - Epizyme itself.

The full post is available to investor members only. Subscribe here.